Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review

The utilization of immune checkpoint inhibitors in oncological treatment has increased in recent years. The therapeutic strategy of targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has altered the management of advanced non-small cell lung carcinoma (NSCLC). Tisleliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Guanghua, Qu, Di, Bai, Yun, Sun, Xiaoke, Li, Yingjue, Yang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407863/
https://www.ncbi.nlm.nih.gov/pubmed/37559583
http://dx.doi.org/10.3892/ol.2023.13974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407863/
https://www.ncbi.nlm.nih.gov/pubmed/37559583
http://dx.doi.org/10.3892/ol.2023.13974

Ejemplares similares